A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.

• Status: Completed
• Trial end date: 2013-01-14
• Target enrollment: 0
• Participant gender: All

Summary

This single arm study will assess the efficacy and safety of MabThera + chlorambucil as induction therapy, followed in responders by maintenance therapy or observation in elderly patients with previously untreated chronic lymphocytic leukemia. During the induction phase patients will receive 2 x 4 weekly courses of chlorambucil followed by 8 x 4 weekly courses of chlorambucil + MabThera. Subsequently, responders will be randomized to receive 12 doses of MabThera given every 8 weeks, or no further treatment. The anticipated time on study treatment is 2+ years, and the target sample size is <100 individuals.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Chlorambucil; Rituximab

Criteria

Inclusion Criteria:

• adult patients, >=60 years of age;

• CD20+ chronic lymphocytic leukemia (CLL);

• no previous treatment for CLL;

• ECOG performance status 0-1.

Exclusion Criteria:

• co-morbid conditions requiring long term use of systemic corticosteroids during study treatment;

• history of severe cardiac disease;

• transformation to aggressive B-cell malignancy.